The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century

被引:45
作者
Barrett, A. John [1 ]
Ito, Sawa [1 ]
机构
[1] NHLBI, Stem Cell Allotransplantat Sect, Hematol Branch, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
CHRONIC MYELOID-LEUKEMIA; CHRONIC GRANULOCYTIC-LEUKEMIA; BCR-ABL TRANSCRIPTS; DONOR LEUKOCYTE TRANSFUSIONS; BONE-MARROW-TRANSPLANTATION; TOTAL-BODY IRRADIATION; QUALITY-OF-LIFE; IMATINIB MESYLATE; ALLOGENEIC TRANSPLANTATION; TYROSINE KINASE;
D O I
10.1182/blood-2014-10-567784
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The introduction of tyrosine kinase inhibitors (TKIs), a treatment of chronic myelogenous leukemia (CML), has largely replaced curative strategies based on allogeneic stem cell transplantation (SCT). Nevertheless, SCT still remains an option for accelerated/blastic-phase and selected chronic-phase CML. Transplant outcomes can be optimized by peritransplant TKIs, conditioning regimen, BCR-ABL monitoring, and relapse management. Controversies exist in transplant timing, pediatric CML, alternative donors, and economics. SCT continues to serve as a platform of "operational cure" for CML with TKIs and immunotherapies.
引用
收藏
页码:3230 / 3235
页数:6
相关论文
共 93 条
[11]   Symptom Distress Predicts Long-Term Health and Well-Being in Allogeneic Stem Cell Transplantation Survivors [J].
Bevans, Margaret F. ;
Mitchell, Sandra A. ;
Barrett, John A. ;
Bishop, Michael R. ;
Childs, Richard ;
Fowler, Daniel ;
Krumlauf, Michael ;
Prince, Patricia ;
Shelburne, Nonniekaye ;
Wehrlen, Leslie ;
Yang, Li .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (03) :387-395
[12]   Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination [J].
Bocchia, Monica ;
Defina, Marzia ;
Aprile, Lara ;
Ippoliti, Micaela ;
Crupi, Rosaria ;
Rondoni, Michela ;
Gozzetti, Alessandro ;
Lauria, Francesco .
NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (10) :600-603
[13]   Fertility after allogeneic haematopoietic stem cell transplantation in childhood and adolescence [J].
Borgmann-Staudt, A. ;
Rendtorff, R. ;
Reinmuth, S. ;
Hohmann, C. ;
Keil, T. ;
Schuster, F. R. ;
Holter, W. ;
Ehlert, K. ;
Keslova, P. ;
Lawitschka, A. ;
Jarisch, A. ;
Strauss, G. .
BONE MARROW TRANSPLANTATION, 2012, 47 (02) :271-276
[14]   Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia [J].
Bornhaeuser, Martin ;
Thiede, Christian ;
Platzbecker, Uwe ;
Kiani, Alexander ;
Oelschlaegel, Uta ;
Babatz, Jana ;
Lehmann, Doris ;
Hoelig, Kristina ;
Radke, Joergen ;
Tuve, Sebastian ;
Wermke, Martin ;
Wehner, Rebekka ;
Jaehnisch, Hanka ;
Bachmann, Michael P. ;
Rieber, E. Peter ;
Schetelig, Johannes ;
Ehninger, Gerhard ;
Schmitz, Marc .
BLOOD, 2011, 117 (26) :7174-7184
[15]  
BUCKNER CD, 1974, EXP HEMATOL, V2, P138
[16]  
BUCKNER CD, 1978, EXP HEMATOL, V6, P96
[17]   Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia [J].
Carpenter, Paul A. ;
Snyder, David S. ;
Flowers, Mary E. D. ;
Sanders, Jean E. ;
Gooley, Theodore A. ;
Martin, Paul J. ;
Appelbaum, Frederick R. ;
Radich, Jerald P. .
BLOOD, 2007, 109 (07) :2791-2793
[18]  
CLIFT RA, 1982, LANCET, V2, P621
[19]   Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction [J].
Copland, Mhairi ;
Hamilton, Ashley ;
EIrick, Lucy J. ;
Baird, Janet W. ;
Allan, Elaine K. ;
Jordanides, Niove ;
Barow, Martin ;
Mountford, Joanne C. ;
Holyoake, Tessa L. .
BLOOD, 2006, 107 (11) :4532-4539
[20]   Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation [J].
Cortes, Jorge ;
Lipton, Jeff H. ;
Rea, Delphine ;
Digumarti, Raghunadharao ;
Chuah, Charles ;
Nanda, Nisha ;
Benichou, Annie-Claude ;
Craig, Adam R. ;
Michallet, Mauricette ;
Nicolini, Franck E. ;
Kantarjian, Hagop .
BLOOD, 2012, 120 (13) :2573-2580